Compass Therapeutics Inc.

NASDAQ CMPX

Data sourced from

and

Daily

Download Data

Compass Therapeutics Inc. Price to Sales Ratio (P/S) on June 03, 2024: 65.80

Compass Therapeutics Inc. Price to Sales Ratio (P/S) is 65.80 on June 03, 2024, a NA change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

Compass Therapeutics Inc. 52-week high Price to Sales Ratio (P/S) is 78.37 on May 14, 2024, which is 19.12% above the current Price to Sales Ratio (P/S).
Compass Therapeutics Inc. 52-week low Price to Sales Ratio (P/S) is 65.80 on June 03, 2024, which is 0.00% below the current Price to Sales Ratio (P/S).
Compass Therapeutics Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 73.42.

NASDAQ: CMPX

Compass Therapeutics Inc.

CEO	Dr. Thomas J. Schuetz M.D., Ph.D.
IPO Date	April 5, 2021
Location	United States
Headquarters	80 Guest Street, Boston, MA, United States, 02135
Employees	32
Sector	Healthcare
Industry	Biotechnology

Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Key trends